

Citations

1. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing *Ephedra sinica* (Ma-huang) as determined by high performance liquid chromatography. *J Pharm Sci* 1998;87:1547-1553.
2. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. *Am J Health Syst Pharm* 2000;57:963-969.
3. Betz JM, Gay ML, Mossoba MM et al. Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Ma Huang. *J AOAC Int* 1997;80:303-315.
4. Zhang JS, Tian Z, Lou ZC. [Quality evaluation of twelve species of Chinese *Ephedra* (ma huang)]. *Yao Xue Xue Bao* 1989;24:865-871.
5. Weiss R. Herbal medicine. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988.
6. Pendell D. Ma Huang, *Ephedra* spp. *Pharmakodynamis: Stimulating Plants, Potions and Herbcraft*. San Francisco: Mercury House; 2002:127-141.
7. WHO. *Herba Ephedrae*. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:145-153.
8. Blumenthal M, Busse W, Goldberg A et al. *The Complete German Commission E Monographs*. Austin: American Botanical Council: Integrative Medicine Communications; 1998:685.
9. Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing *Ephedra sinica* (ma huang). *Ther Drug Monit* 1998;20:439-445.
10. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (*Ephedra*) under different conditions of preparation. *Toxicol Sci* 2000;56:424-430.
11. Nikaido T, Ohmoto T, Kuge T et al. [The study on Chinese herbal medicinal prescription with enzyme inhibitory activity. III. The study of mao-to with adenosine 3',5'-cyclic monophosphate phosphodiesterase]. *Yakugaku Zasshi* 1990;110:504-508.
12. Cantox. Safety assessment and determination of a tolerable upper limit for ephedra. Mississauga, ON, Canada: Cantox Health Sciences International; 2000.
13. Shekelle PG, Hardy ML, Morton SC et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. *Evid Rep Technol Assess (RAND)* 2003;76.
14. Shekelle PG, Hardy ML, Morton SC et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. *JAMA* 2003;289:1537-1545.
15. Pittler M, Ernst E. Complementary therapies for reducing body weight: a systematic review. *Int J Obes Relat Metab Disord* 2005.
16. Milone M, Engel AG. Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol. *Brain Res* 1996;740:346-352.
17. El Hemaly AK. Nocturnal enuresis: pathogenesis and treatment. *Int Urogynecol J Pelvic Floor Dysfunct* 1998;9:129-131.
18. Schaneberg BT, Crockett S, Bedir E, Khan IA. The role of chemical fingerprinting: application to *Ephedra*. *Phytochemistry* 2003;62:911-918.
19. Sulzer D, Sonders M, Poulsen N, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. *Prog Neurobiol* 2005;75:406-433.
20. Sever PS, Dring LG, Williams RT. The metabolism of ephedrine in man. *Eur J Clin Pharmacol* 1975;9:193-198.
21. Wilkinson GR, Beckett AH. Absorption, metabolism, and excretion of the ephedrine in man. II. Pharmacokinetics. *J Pharm Sci* 1968;57:1933-1938.
22. Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. *Clin Pharmacol Ther* 1971;12:62-67.
23. Brater DC, Kaojarern S, Benet LZ et al. Renal excretion of pseudoephedrine. *Clin Pharmacol Ther* 1980;28:690-694.
24. Astrup A, Breum L, Toubro S et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. *Int J Obes Relat Metab Disord* 1992;16:269-277.
25. Astrup A, Breum L, Toubro S et al. Ephedrine and weight loss. *Int J Obes Relat Metab Disord* 1992;16:715.
26. Astrup A, Buemann B, Christensen NJ et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. *Metabolism* 1992;41:686-688.
27. Astrup A, Madsen J, Holst JJ, Christensen NJ. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. *Metabolism* 1986;35:260-265.
28. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S41-43.
29. Astrup A, Toubro S, Cannon S et al. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. *Metabolism* 1991;40:323-329.

Citations and Reference Literature: Ephedra

30. Vukovich MD, Schoorman R, Heilman C et al. Caffeine–herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure. *Clin Exp Pharmacol Physiol* 2005;32:47-53.
31. Hackman RM, Havel PJ, Schwartz HJ et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. *Int J Obes (Lond)* 2006;30:1545-1546.
32. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies. *Am J Clin Nutr* 1986;43:388-394.
33. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. *Int J Obes* 1986;10:467-481.
34. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism* 1992;41:1233-1241.
35. Myers MG. Effects of caffeine on blood pressure. *Arch Intern Med* 1988;148:1189-1193.
36. Myers MG. Caffeine and cardiac arrhythmias. *Ann Intern Med* 1991;114:147-150.
37. McBride BF, Karapanos AK, Krudysz A et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. *JAMA* 2004;291:216-221.
38. Ray S, Phadke S, Patel C et al. Short-term and long-term in vivo exposure to an ephedra- and caffeine-containing metabolic nutrition system does not induce cardiotoxicity in B6C3F1 mice. *Arch Toxicol* 2005;79:330-340.
39. Nikaido T, Iizuka S, Okada N et al. [The study of Chinese herbal medicinal prescription with enzyme inhibitory activity. VI. The study of makyo-kanseki-to with adenosine 3',5'-cyclic monophosphate phosphodiesterase]. *Yakugaku Zasshi* 1992;112:124-128.
40. Weinberger M, Bronsky E, Bensch GW et al. Interaction of ephedrine and theophylline. *Clin Pharmacol Ther* 1975;17:585-592.
41. Tinkelman DG, Avner SE. Ephedrine therapy in asthmatic children: clinical tolerance and absence of side effects. *JAMA* 1977;237:553-557.
42. Boozer CN, Daly PA, Homel P et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *Int J Obes Relat Metab Disord* 2002;26:593-604.
43. Yanovski SZ, Yanovski JA. Obesity. *N Engl J Med* 2002;346:591-602.
44. Brooks SM, Sholiton LJ, Werk EE Jr, Altenau P. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. *J Clin Pharmacol* 1977;17:308-318.
45. Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. *Drugs* 1979;18:113-121.
46. Flegin OT, Morgan DH, Oates JA, Shand DG. The mechanism of the reversal of the effect of guanethidine by amphetamines in cat and man. *Br J Pharmacol* 1970;39:253P-254P.
47. Gulati OD, Dave BT, Gokhale SD, Shah KM. Antagonism of adrenergic neuron blockade in hypertensive subjects. *Clin Pharmacol Ther* 1966;7:510-514.
48. Starr KJ, Petrie JC. Drug interactions in patients on long-term oral anticoagulant and antihypertensive adrenergic neuron-blocking drugs. *Br Med J* 1972;4:133-135.
49. Stockley I. *Stockley's Drug Interactions*. 6th ed. London: Pharmaceutical Press; 2002.
50. Hoffman B, Lefkowitz R. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman J, Limbird L, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. New York: McGraw-Hill; 1995.
51. Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. *J Ethnopharmacol* 1991;32:201-208.
52. Ulus IH, Maher TJ, Wurtman RJ. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. *Biochem Pharmacol* 2000;59:1611-1621.
53. Scorza MC, Carrau C, Silveira R et al. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. *Biochem Pharmacol* 1997;54:1361-1369.
54. Dingemans J. An update of recent moclobemide interaction data. *Int Clin Psychopharmacol* 1993;7:167-180.
55. Martyr JW, Orlikowski CE. Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor. *Anaesthesia* 1996;51:1150-1152.
56. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. *J Accid Emerg Med* 1995;12:49-51.
57. Furukawa T, Morishita H. Modifications of responses to adrenergic drugs in arterial strip by treatment in vivo with ephedrine and reserpine. *Jpn J Pharmacol* 1975;25:441-451.
58. Kim JM, Stevenson CE, Mathewson HS. Hypertensive reactions to phenylephrine eyedrops in patients with sympathetic denervation. *Am J Ophthalmol* 1978;85:862-868.
59. Nishikawa T, Kimura T, Taguchi N, Dohi S. Oral clonidine preanesthetic medication augments the pressor responses to intravenous ephedrine in awake or anesthetized patients. *Anesthesiology* 1991;74:705-710.

Citations and Reference Literature: Ephedra

60. Lee A, Ngan Kee WD, Gin T. Prophylactic ephedrine prevents hypotension during spinal anesthesia for cesarean delivery but does not improve neonatal outcome: a quantitative systematic review. *Can J Anaesth* 2002;49:588-599.
61. Kanaya N, Satoh H, Seki S et al. Propofol anesthesia enhances the pressor response to intravenous ephedrine. *Anesth Analg* 2002;94:1207-1211, table of contents.
62. Webb AA, Shipton EA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for caesarean section. *Can J Anaesth* 1998;45:367-369.
63. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. *JAMA* 2001;286:208-216.
64. Konno C, Mizuno T, Hikino H. Isolation and hypoglycemic activity of ephedrans A, B, C, D and E, glycans of *Ephedra distachya* herbs. *Planta Med* 1985;162-163.
65. Xiu LM, Miura AB, Yamamoto K et al. Pancreatic islet regeneration by ephedrine in mice with streptozotocin-induced diabetes. *Am J Chin Med* 2001;29:493-500.
66. Strosberg AD. Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status. *Trends Pharmacol Sci* 1997;18:449-454.
67. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. *Biochem Pharmacol* 1999;58:807-810.
68. Dionne IJ, Turner AN, Tchernof A et al. Identification of an interactive effect of beta3- and alpha2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women. *Diabetes* 2001;50:91-95.
69. Buscher R, Herrmann V, Insel PA. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. *Trends Pharmacol Sci* 1999;20:94-99.
70. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. *N Engl J Med* 2000;343:1826-1832.
71. Morgenstern LB, Viscoli CM, Kernan WN et al. Use of Ephedra-containing products and risk for hemorrhagic stroke. *Neurology* 2003;60:132-135.
72. Inokuchi J, Okabe H, Yamauchi T et al. Inhibitors of angiotensin-converting enzyme in crude drugs. II. *Chem Pharm Bull (Tokyo)* 1985;33:264-269.
73. White LM, Gardner SF, Gurley BJ et al. Pharmacokinetics and cardiovascular effects of ma-huang (*Ephedra sinica*) in normotensive adults. *J Clin Pharmacol* 1997;37:116-122.
74. Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. *Am J Kidney Dis* 1998;32:153-159.
75. Yokozawa T, Fujioka K, Oura H et al. Decrease in uremic toxins, a newly found beneficial effect of *Ephedrae Herba*. *Phytother Res* 1995;34:277-282.
76. Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. *Exp Biol Med (Maywood)* 2004;229:698-704.
77. Dentali SJ. Comment on Citrus aurantium minireview. *Exp Biol Med (Maywood)* 2005;230:102; discussion 103.
78. Haaz S, Fontaine KR, Cutter G et al. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obes Rev* 2006;7:79-88.